Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food Labeling; Notification Procedures for Statements on Dietary Supplements, 18351-18352 [2013-06823]
Download as PDF
Federal Register / Vol. 78, No. 58 / Tuesday, March 26, 2013 / Notices
any provision by Congress regarding the
decision by HHS to add the class to the
SEC.
FOR FURTHER INFORMATION CONTACT:
Stuart L. Hinnefeld, Director, Division
of Compensation Analysis and Support,
NIOSH, 4676 Columbia Parkway, MS
C–46, Cincinnati, OH 45226, Telephone
1–877–222–7570. Information requests
can also be submitted by email to
DCAS@CDC.GOV.
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. 2013–06844 Filed 3–25–13; 8:45 am]
BILLING CODE 4163–19–P
1–877–222–7570. Information requests
can also be submitted by email to
DCAS@CDC.GOV.
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. 2013–06846 Filed 3–25–13; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Determination Concerning a Petition
To Add a Class of Employees to the
Special Exposure Cohort
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Designation of a Class of Employees
for Addition to the Special Exposure
Cohort
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
SUMMARY: HHS gives notice of a
decision to designate a class of
employees from the Battelle
Laboratories King Avenue facility in
Columbus, Ohio, as an addition to the
Special Exposure Cohort (SEC) under
the Energy Employees Occupational
Illness Compensation Program Act of
2000. On March 6, 2013, the Secretary
of HHS designated the following class of
employees as an addition to the SEC:
SUMMARY: HHS gives notice of a
determination concerning a petition to
add a class of employees from the
Hanford site in Richland, Washington,
to the Special Exposure Cohort (SEC)
under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 (EEOICPA), 42
U.S.C. 7384q. On March 6, 2013, the
Secretary of HHS determined that the
following class of employees does not
meet the statutory criteria for addition
to the SEC as authorized under
EEOICPA:
All personnel who were internally
monitored (urine or fecal), who worked at the
Plutonium Finishing Plant in the 200 Area at
the Hanford site, from January 1, 1987,
through December 31, 1989.
srobinson on DSK4SPTVN1PROD with NOTICES
All Atomic Weapons Employees who
worked at the King Avenue facility owned by
Battelle Laboratories in Columbus, Ohio,
during the period from April 16, 1943,
through June 30, 1956, for a number of work
days aggregating at least 250 work days,
occurring either solely under this
employment or in combination with work
days within the parameters established for
one or more other classes of employees
included in the Special Exposure Cohort.
John Howard,
Director, National Institute for Occupational
Safety and Health.
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
ACTION: Notice.
SUMMARY: HHS gives notice of a
determination concerning a petition to
add a class of employees from General
Steel Industries in Granite City, Illinois,
to the Special Exposure Cohort (SEC)
under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 (EEOICPA), 42
U.S.C. 7384q. On March 6, 2013, the
Secretary of HHS determined that the
following class of employees does not
meet the statutory criteria for addition
to the SEC as authorized under
EEOICPA:
All individuals who worked in any
location at the General Steel Industries site,
located at 1417 State Street, Granite City,
Illinois, from January 1, 1953, through June
30, 1966, and/or during the residual radiation
period from July 1, 1966, through December
31, 1992.
FOR FURTHER INFORMATION CONTACT:
Stuart L. Hinnefeld, Director, Division
of Compensation Analysis and Support,
National Institute for Occupational
Safety and Health (NIOSH), 4676
Columbia Parkway, MS C–46,
Cincinnati, OH 45226, Telephone
1–877–222–7570. Information requests
can also be submitted by email to
DCAS@CDC.GOV.
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. 2013–06845 Filed 3–25–13; 8:45 am]
BILLING CODE 4163–19–P
FOR FURTHER INFORMATION CONTACT:
This designation will become
effective on April 5, 2013, unless
Congress provides otherwise prior to the
effective date. After this effective date,
HHS will publish a notice in the
Federal Register reporting the addition
of this class to the SEC or the result of
any provision by Congress regarding the
decision by HHS to add the class to the
SEC.
FOR FURTHER INFORMATION CONTACT:
Stuart L. Hinnefeld, Director, Division
of Compensation Analysis and Support,
NIOSH, 4676 Columbia Parkway, MS
C–46, Cincinnati, OH 45226, Telephone
18351
VerDate Mar<15>2010
19:07 Mar 25, 2013
Jkt 229001
Stuart L. Hinnefeld, Director, Division
of Compensation Analysis and Support,
National Institute for Occupational
Safety and Health (NIOSH), 4676
Columbia Parkway, MS C–46,
Cincinnati, OH 45226, Telephone 1–
877–222–7570. Information requests can
also be submitted by email to
DCAS@CDC.GOV.
[FR Doc. 2013–06849 Filed 3–25–13; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0032]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Food Labeling;
Notification Procedures for Statements
on Dietary Supplements
AGENCY:
BILLING CODE 4150–28–P
Food and Drug Administration,
HHS.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Determination Concerning a Petition
To Add a Class of Employees to the
Special Exposure Cohort
National Institute for
Occupational Safety and Health
AGENCY:
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
E:\FR\FM\26MRN1.SGM
26MRN1
18352
Federal Register / Vol. 78, No. 58 / Tuesday, March 26, 2013 / Notices
Fax written comments on the
collection of information by April 25,
2013.
DATES:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0331. Also
include the FDA docket number found
in brackets in the heading of this
document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5733, domini.bean@fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Food Labeling; Notification Procedures
for Statements on Dietary
Supplements—21 CFR 101.93 (OMB
Control Number 0910–0331)—Extension
Section 403(r)(6) of the FD&C Act (21
U.S.C. 343(r)(6)) requires that FDA be
notified by manufacturers, packers, and
distributors of dietary supplements that
they are marketing a dietary supplement
product that bears on its label or in its
labeling a statement provided for in
section 403(r)(6). Section 403(r)(6) of the
FD&C Act requires that FDA be notified,
with a submission about such
statements, no later than 30 days after
the first marketing of the dietary
supplement. Information that is
required in the submission includes: (1)
The name and address of the
manufacturer, packer, or distributor of
the dietary supplement product; (2) the
text of the statement that is being made;
(3) the name of the dietary ingredient or
supplement that is the subject of the
statement; (4) the name of the dietary
supplement (including the brand name);
and (5) a signature of a responsible
individual who can certify the accuracy
of the information presented, and who
must certify that the information
contained in the notice is complete and
accurate, and that the notifying firm has
substantiation that the statement is
truthful and not misleading.
The procedural regulation for this
program is codified at 21 CFR 101.93.
Section 101.93 provides submission
procedures and identifies the
information that must be included in
order to meet the requirements of
section 403 of the FD&C Act.
Description of Respondents:
Respondents to this collection of
information include manufacturers,
packers, or distributors of dietary
supplements that bear section 403(r)(6)
of the FD&C Act statements on their
labels or labeling.
In the Federal Register of January 18,
2013 (78 FR 4153), FDA published a 60day notice requesting public comment
on the proposed collection of
information. FDA received one letter in
response to the notice. One comment in
the letter suggested that electronic
submission could potentially decrease
the reporting burden. FDA agrees and is
in the process of developing a method
of receiving submissions electronically.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
21 CFR section
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
101.93
2,200
1
2,200
0.75
1,650
srobinson on DSK4SPTVN1PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
We believe that there will be minimal
burden on the industry to generate
information to meet the requirements of
section 403 of the FD&C Act in
submitting information regarding
section 403(r)(6) statements on labels or
in labeling of dietary supplements. We
are requesting only information that is
immediately available to the
manufacturer, packer, or distributor of
the dietary supplement that bears such
a statement on its label or in its labeling.
We estimate that, each year,
approximately 2,200 firms will submit
the information required by section 403
of the FD&C Act. We estimate that a firm
will require 0.75 hours to gather the
information needed and prepare a
submission, for a total of 1,650 hours
(2,200 × 0.75). This estimate is based on
the average number of notification
submissions received by us in the
preceding 3 years.
Dated: March 20, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–06823 Filed 3–25–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–P–0649]
Determination That QUESTRAN
(Cholestyramine for Oral Suspension,
USP), Equivalent to 4 Grams, and
QUESTRAN LIGHT (Cholestyramine for
Oral Suspension, USP), Equivalent to 4
Grams, Were Not Withdrawn From Sale
for Reasons of Safety or Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
19:07 Mar 25, 2013
Jkt 229001
PO 00000
Frm 00048
Fmt 4703
FOR FURTHER INFORMATION CONTACT:
Carolina M. Wirth, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 6282,
Silver Spring, MD 20993–0002, 301–
796–3602.
In 1984,
Congress enacted the Drug Price
Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
SUPPLEMENTARY INFORMATION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has determined
VerDate Mar<15>2010
that QUESTRAN (cholestyramine for
oral suspension, USP), equivalent to
(EQ) 4 grams (g), and QUESTRAN
LIGHT (cholestyramine for oral
suspension, USP), EQ 4 g, were not
withdrawn from sale for reasons of
safety or effectiveness. This
determination means that FDA will not
begin procedures to withdraw approval
of the abbreviated new drug
applications (ANDAs) that refer to these
drugs, and it will allow FDA to approve
ANDAs that refer to these drugs as long
as they meet relevant legal and
regulatory requirements.
Sfmt 4703
E:\FR\FM\26MRN1.SGM
26MRN1
Agencies
[Federal Register Volume 78, Number 58 (Tuesday, March 26, 2013)]
[Notices]
[Pages 18351-18352]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-06823]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0032]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Food Labeling;
Notification Procedures for Statements on Dietary Supplements
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
[[Page 18352]]
DATES: Fax written comments on the collection of information by April
25, 2013.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0331.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B,
Rockville, MD 20850, 301-796-5733, domini.bean@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Food Labeling; Notification Procedures for Statements on Dietary
Supplements--21 CFR 101.93 (OMB Control Number 0910-0331)--Extension
Section 403(r)(6) of the FD&C Act (21 U.S.C. 343(r)(6)) requires
that FDA be notified by manufacturers, packers, and distributors of
dietary supplements that they are marketing a dietary supplement
product that bears on its label or in its labeling a statement provided
for in section 403(r)(6). Section 403(r)(6) of the FD&C Act requires
that FDA be notified, with a submission about such statements, no later
than 30 days after the first marketing of the dietary supplement.
Information that is required in the submission includes: (1) The name
and address of the manufacturer, packer, or distributor of the dietary
supplement product; (2) the text of the statement that is being made;
(3) the name of the dietary ingredient or supplement that is the
subject of the statement; (4) the name of the dietary supplement
(including the brand name); and (5) a signature of a responsible
individual who can certify the accuracy of the information presented,
and who must certify that the information contained in the notice is
complete and accurate, and that the notifying firm has substantiation
that the statement is truthful and not misleading.
The procedural regulation for this program is codified at 21 CFR
101.93. Section 101.93 provides submission procedures and identifies
the information that must be included in order to meet the requirements
of section 403 of the FD&C Act.
Description of Respondents: Respondents to this collection of
information include manufacturers, packers, or distributors of dietary
supplements that bear section 403(r)(6) of the FD&C Act statements on
their labels or labeling.
In the Federal Register of January 18, 2013 (78 FR 4153), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. FDA received one letter in response to the
notice. One comment in the letter suggested that electronic submission
could potentially decrease the reporting burden. FDA agrees and is in
the process of developing a method of receiving submissions
electronically.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
21 CFR section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
101.93 2,200 1 2,200 0.75 1,650
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
We believe that there will be minimal burden on the industry to
generate information to meet the requirements of section 403 of the
FD&C Act in submitting information regarding section 403(r)(6)
statements on labels or in labeling of dietary supplements. We are
requesting only information that is immediately available to the
manufacturer, packer, or distributor of the dietary supplement that
bears such a statement on its label or in its labeling. We estimate
that, each year, approximately 2,200 firms will submit the information
required by section 403 of the FD&C Act. We estimate that a firm will
require 0.75 hours to gather the information needed and prepare a
submission, for a total of 1,650 hours (2,200 x 0.75). This estimate is
based on the average number of notification submissions received by us
in the preceding 3 years.
Dated: March 20, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-06823 Filed 3-25-13; 8:45 am]
BILLING CODE 4160-01-P